From ADCs to radiopharma: How AstraZeneca is trying to ‘redefine oncology care’

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. Now, the U.K.-based pharma is overseeing a range of clinical trials to determine whether these cancer bets will pay off.